Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Antimicrobial resistance (AMR) is one the most pressing challenges facing the world today. Common infections that were once easily treated by antibiotics are becoming life-threatening again. By 2050 it is predicted that over 10 million deaths will be caused by drug-resistant infections every year.

IOI DPhil student Shonnette Premchand-Branker preparing plates in the lab

At the Ineos Oxford Institute for antimicrobial research (IOI), created in 2021 to advance antimicrobial research, Oxford’s graduate students are among those contributing to the search for solutions to tackle this growing threat to global health.

34 DPhil students from around the world are based at the IOI, each part of a focused research project that works to develop new antibiotics or study the spread and impact of AMR around the world.

Among them is Kate Cook, a DPhil student, who is currently undertaking research in Murtala Muhammad Specialist Hospital in Kano, Nigeria to investigate the causes of wound infections in surgical and orthopedic wards. Through her work, she aims to understand the role of insects like flies, cockroaches and ants in spreading bacteria in tropical climates.

 Working closely with two research assistants in the hospital – Maryam and Firdausi – Kate acts as a microbiological detective, identifying which kinds of bacteria are causing infections in patients, then investigating whether these bacteria are also present on hospital surfaces, and in insects caught on the wards.

 

Read the full story on the University of Oxford website.

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.